Nova Scotia has the highest cancer incidence rate of any province in Canada, followed by Newfoundland and Labrador, and Ontario. However, Nunavut has the highest cancer mortality rate of the provinces. In Nunavut there are around 310 deaths from cancer per 100,000 population, compared to a rate of 218 deaths per 100,000 in Newfoundland and Labrador.

New cancer cases

As of 2023, there were around 513 new cancer cases in Canada per 100,000 population. The most common types of cancer in Canada include lung and bronchus cancer, breast cancer, and prostate cancer. Breast cancer is the most common type of cancer among women, while prostate cancer is the second most common type among men. Men have slightly higher rates of lung and bronchus cancer and colorectal cancer.

Cancer mortality

Lung and bronchus cancers have the highest mortality rate of any cancer in Canada, followed by colorectal and pancreas cancer. Men in Canada have around a five percent chance of dying as a result of lung and bronchus cancer. The lifetime probability of dying from any cancer type for males in Canada is around 24 percent.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

The incidence rate of breast cancer in Manitoba is estimated to be around 122 cases per 100,000 population in females in 2023. This statistic depicts the estimated incidence rate of the three most common cancers among females in Canada by province, as of 2023.

Age-standardized rate of cancer incidence for selected primary sites of cancer, by sex, for health regions, on a three-year average basis.

This statistic displays age-standardized rate of all cancer types among males in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2019, the incidence rate for all cancer cases reached 548 per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

This table contains 30810 series, with data for years 2001/2003 - 2013/2015 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (158 items: Canada; Newfoundland and Labrador; Eastern Regional Health Authority, Newfoundland and Labrador; Central Regional Health Authority, Newfoundland and Labrador; ...);  Sex (3 items: Both sexes; Males; Females);  Selected sites of cancer (ICD-O-3) (5 items: All invasive primary cancer sites (including in situ bladder); Colon, rectum and rectosigmoid junction cancer; Bronchus and lung cancer; Female breast cancer; ...);  Characteristics (13 items: Number of new cancer cases; Cancer incidence (rate per 100,000 population); Low 95% confidence interval, cancer incidence (rate per 100,000 population); High 95% confidence interval, cancer incidence (rate per 100,000 population); ...).

The incidence rate of prostate cancer in Manitoba was estimated to be 119 cases per 100,000 population in males in 2023. This statistic displays the estimated incidence rate of the three most common cancers among males in Canada by province, as of 2023.

This statistic displays the age-standardized rate of all cancer cases among females in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2023, the incidence rate for all cancer cases was predicted to reach 481 per 100,000 population among females. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

This web map utilize the 2015 boundaries of health regions in provinces and the territories of Canada. Boundaries are from Statistics Canada. Each boundary was given an incidence rate per 100,000 population taken from the source.Source: Cancer incidence, by selected sites of cancer and sex, three-year average, Canada, provinces, territories and health regions (2015 boundaries)

In 2023, it was estimated that the mortality rate for cancer in Manitoba would be 192.4 deaths due to per 100,000 population. This statistic displays the estimated mortality rate of cancer in Canada by province in 2023.

Number and rate of new cancer cases by stage at diagnosis from 2011 to the most recent diagnosis year available. Included are colorectal, lung, breast, cervical and prostate cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

This layer utilize the 2015 boundaries of health regions in provinces and the territories of Canada. Boundaries are from Statistics Canada. Each boundary are given an incidence rate per 100,000 population taken from their data layer Cancer incidence, by selected sites of cancer and sex, three-year average, Canada, provinces, territories and health regions (2015 boundaries)

This statistic displays the age-standardized rate of colorectal cancer among males in Canada between 1988 and 2019 with a forecast for 2020 to 2023. In 2023, the incidence rate for colorectal cancer cases was predicted to be 60.5 per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

This map uses age-standardized ratios to further aid in regional comparisons. A value of 1.0 would indicate that the region rate is identical to the overall Canadian rate; a value greater than 1.0 would indicate that the rate for that region is higher than the Canadian rate; and, in turn, a ratio value less than 1.0 would indicate that the rate for the specific region is lower than the Canadian rate. Statistically low incidences of breast cancer are found in Newfoundland and Labrador, the territories, and northern areas of most provinces. Otherwise, each province has one or more pockets of significantly high breast cancer incidence. Health status refers to the state of health of a person or group, and measures causes of sickness and death. It can also include people’s assessment of their own health.

Background: Over 90% of skin cancers including cutaneous melanoma (CM) are related directly to sun exposure. Despite extensive knowledge on ultraviolet radiation’s (UVR) detrimental impact, many still fail to implement sun protection/sun avoidance. Human behavior, attitudes, and cultural norms of individuals and communities heavily depend on the surrounding climate/environment. In many instances, the climate shapes the culture/norms of the society. Canada has vast geographic/environmental differences. Methods: In the current ecological study, we sought to examine the relationship between various geographic and environmental factors and the distribution of CM incidence by Forward Sortation Area (FSA) postal code across Canada. CM incidence data were extracted from the Canadian Cancer Registry, while environmental data were extracted from the Canadian Urban Environmental Health Research Consortium (greenspace, as measured by the normalized difference vegetation index; annual highest temperature; absolute number and average length of yearly heat events; annual total precipitation [rain and snow]; absolute number and average length of events with precipitation [rain and snow]; and summer UVR index). The above geographic/environmental data by FSA were correlated with the respective CM incidence employing negative binomial regression model. Results: Our analysis highlights that increases in annual average temperature, summer UVR, and greenspace were associated with higher expected incidence of CM cases, while higher number of annual heat events together with highest annual temperature and higher average number of annual rain events were associated with a decrease in CM incidence rate. This study also highlights regional variation in environmental CM risk factors in Canada. Conclusions: This national population-based study presents clinically relevant conclusions on weather/geographic variations associated with CM incidence in Canada and will help refine targeted CM prevention campaigns by understanding unique weather/geographic variations in high-risk regions.

This statistic depicts age-standardized rates of stomach cancer among males in Canada between 1988 and 2013, with a forecast for 2014 to 2017. In 1990, the incidence rate for stomach cancer cases reached 21.2 per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

One woman in nine can expect to develop breast cancer during her lifetime and one in 25 will die from the disease. Statistically low incidences of breast cancer are found in Newfoundland and Labrador, the territories, and northern areas of most provinces. Otherwise, each province has one or more pockets of significantly high breast cancer incidence. These are often located in more southerly areas, but they do not seem to be restricted to either urban or rural areas alone. Breast cancer rates are a health status indicator. They can be used to help assess health conditions. Health status refers to the state of health of a person or group, and measures causes of sickness and death. It can also include people’s assessment of their own health.

This statistic displays the age-standardized rate of prostate cancer among males in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2019, the incidence rate for prostate cancer cases reached 118 per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

Snapshot img

Cancer Registry Software Market Size 2024-2028

The cancer registry software market size is forecast to increase by USD 97.1 million at a CAGR of 12.75% between 2023 and 2028.

The growing prevalence of cancer cases is the key driver of the cancer registry software market. CDC is a key player, specializing in providing advanced cancer registry software solutions, including Registry Plus. These systems facilitate accurate and efficient data management for healthcare organizations, enabling effective tracking, analysis, and reporting of cancer patient information as well as supporting cancer immunotherapy and cancer diagnostics. By supporting improved patient care and research outcomes, CDC's solutions are essential in addressing the increasing demand for comprehensive cancer data management. 
Additionally, data privacy and security concerns are driving the market, as healthcare organizations prioritize protecting sensitive patient information. These trends are shaping the market, which is expected to continue its growth trajectory In the coming years.

What will be the Size of the Cancer Registry Software Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the increasing incidence of cancer and the need for efficient and accurate data management In the healthcare industry. With the adoption of Electronic Health Records (EHRs) and the shift towards evidence-based medicine, cancer registry software solutions have become essential tools for medical professionals to track cancer treatment, therapeutics, and patient outcomes. 
These solutions enable the collection and analysis of data on cancer prevalence, diagnostics, and specific area-focused cancer incidence. They provide valuable insights into cancer-specific outcomes, including chemotherapy, surgery, supportive treatments, and post-endoscopic resection. Furthermore, regulatory guidance documents mandate the use of cancer registry software to ensure compliance with healthcare standards and reduce healthcare costs.
Medical professionals rely on these software solutions to improve patient care and support the ongoing research and development of new cancer treatments.

How is this Cancer Registry Software Industry segmented and which is the largest segment?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premise
  Cloud


Component

  Commercial
  Public


Geography

  North America

    Canada
    US


  Europe

    Germany
    Italy


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period. Cancer registry software plays a pivotal role in managing data related to cancer cases for government hospitals and third-party agencies. This software facilitates the collection, management, and analysis of data on cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and agencies can target high-risk populations, address geographic disparities, and recognize emerging cancer types. Cancer registry software enhances the quality of cancer care by enabling the evaluation of treatment practices against clinical guidelines and benchmarking outcomes against standards. The software supports seamless data integration and interoperability with healthcare systems, ensuring coordinated care for cancer patients.

Medical professionals and patients alike benefit from improved cancer care through evidence-based medicine, cancer-specific outcomes, and research institutes. Software solutions cater to various cancer types, including lung cancer, and support cancer staging, treatment, disease management, diagnostics, chemo, surgery, and supportive therapies. These solutions integrate with electronic health records (EHR), enabling secure data storage and access to essential health information. Data security and security protocols are prioritized to protect patient privacy and prevent medical identity theft. Cancer registry software supports population health management, healthcare cost containment, and chronic disease management. It aligns with healthcare quality goals and streamlines hospital workflows, making it an essential tool for oncology departments, clinics, hospitals, medical practices, pharmaceutical, biotech, and medical de

Number and proportion of prevalent cancer cases for two-, five-, ten- and twenty-year prevalence durations from January 1st,1994 to the most recent index date available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.